Astrazeneca (AZN) Total Non-Current Liabilities (2009 - 2026)
Astrazeneca (AZN) posted quarterly Total Non-Current Liabilities of $33.9 billion for Q2 2026, little changed year-over-year from $34.1 billion in Q2 2025, and up 199.56% quarter-over-quarter from -$34.1 billion in Q1 2026.
Astrazeneca (AZN) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Astrazeneca's Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $33.9 billion for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities changed 0.49% year-over-year to $33.9 billion; the TTM figure through Jun 2026 stood at $33.9 billion (changed 0.49% YoY), while the FY2025 annual figure was $34.7 billion, down 1.59% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $33.9 billion, up from -$34.1 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $35.3 billion in Q4 2024, with the low at -$41.2 billion in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is -$34.1 billion (2022), against an average of -$12.5 billion.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities plunged 79.9% in 2022, then jumped 194.2% in 2025.
- Astrazeneca's Total Non-Current Liabilities stood at $33.1 billion in 2022, then fell by 5.19% to $31.4 billion in 2023, then advanced by 12.37% to $35.3 billion in 2024, then retreated by 1.59% to $34.7 billion in 2025, then decreased by 2.38% to $33.9 billion in 2026.
- Business Quant data shows AZN's Total Non-Current Liabilities at $33.9 billion in Q2 2026, -$34.1 billion in Q1 2026, and $34.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.03 Bn | 631.27 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 469.49 Bn | 462.92 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 375.14 Bn | 368.00 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 302.92 Bn | 295.23 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.73 Bn | 252.83 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 236.80 Bn | 222.81 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 182.42 Bn | 179.24 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.16 Bn | 101.99 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Sanofi | 55.18 Bn | 47.80 Bn | 10.79 Bn | 32.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.91 Bn |
| Mar 31, 2026 | -34.06 Bn |
| Dec 31, 2025 | 34.74 Bn |
| Sep 30, 2025 | -34.43 Bn |
| Jun 30, 2025 | 34.08 Bn |
| Mar 31, 2025 | -35.99 Bn |
| Dec 31, 2024 | 35.30 Bn |
| Sep 30, 2024 | -38.19 Bn |
| Jun 30, 2024 | -36.18 Bn |
| Mar 31, 2024 | -35.89 Bn |
| Dec 31, 2023 | 31.41 Bn |
| Sep 30, 2023 | -30.28 Bn |
| Jun 30, 2023 | -32.75 Bn |
| Mar 31, 2023 | -36.02 Bn |
| Dec 31, 2022 | 33.13 Bn |
| Sep 30, 2022 | -34.18 Bn |
| Jun 30, 2022 | -38.81 Bn |
| Mar 31, 2022 | -41.17 Bn |
| Dec 31, 2021 | 43.48 Bn |
| Sep 30, 2021 | -43.66 Bn |